Srishti Chakravorty
Srishti Chakravorty has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Albert B. Jeon
Quantitative Biosciences, Merck & Co., Inc., Rahway, New Jersey
15 shared publications - Douglas C. Wilson
Quantitative Biosciences, Merck & Co., Inc., Rahway, New Jersey
15 shared publications - Eunseon Ahn
Discovery Oncology, Merck & Co., Inc., Rahway, New Jersey
15 shared publications - Jin-Hwan Han
Discovery Oncology, Merck & Co Inc, Rahway, New Jersey, USA
15 shared publications - Komal Pradhan
Discovery Oncology, Merck & Co., Inc., Rahway, New Jersey
15 shared publications - Manoj Charati
Merck & Co., Inc., 213 E. Grand Avenue, South San Francisco, California 94080, United States
15 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
EMT6.hHER2 tumors upon T-MMAE or T-DXd ADC -/+ anti-PD-1 mAb treatment.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
EMT6.hHER2 tumors upon T-MMAE or T-DXd ADC -/+ anti-PD-1 mAb treatment.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Antibody–drug conjugates (ADC) have recently emerged as an effective treatment option for cancer. Although the fundamental mechanisms of direct tumor cell killing by various ADC payloads have been established, their impact on the tumor microenvironment (TME) remains underexplored. To investigate this fundamental question, we generated an immunocompetent murine tumor model that maintains the expression of a clinically validated tumor-associated antigen, human HER2. We evaluated two ADCs with a shared antibody framework: trastuzumab linked to the microtubule inhibitor monomethyl auristatin E (T-MMAE) and the topoisomerase inhibitor deruxtecan (T-DXd). Treatment with T-MMAE led to a significant increase in immune cell infiltration, whereas T-DXd–treated tumors had fewer immune cells albeit comparable tumor cytotoxicity. When combined with anti–PD-1 immunotherapy, similar additive effects on the primary antitumor response were observed for both ADCs. A key qualitative difference between the two ADCs was observed in the phenotypes of myeloid APCs; T-MMAE treatment resulted in greater immune cell infiltration within the tumor, including macrophages that showed increased gene expression of F4/80, CD206, and IL10RA. In contrast, tumors treated with T-DXd exhibited a lower proportion of macrophages, but APCs in these tumors displayed heightened levels of the CD80 costimulatory molecule. The secondary antitumor response mediated by memory CD8+ T cells was crucial for the formation of immunologic memory induced by both ADCs. Therefore, our findings reveal that, after ADC-mediated tumor cytotoxicity, different ADC payloads elicit distinct immunologic responses characterized by varying levels of myeloid cell activation within the TME.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Antibody–drug conjugates (ADC) have recently emerged as an effective treatment option for cancer. Although the fundamental mechanisms of direct tumor cell killing by various ADC payloads have been established, their impact on the tumor microenvironment (TME) remains underexplored. To investigate this fundamental question, we generated an immunocompetent murine tumor model that maintains the expression of a clinically validated tumor-associated antigen, human HER2. We evaluated two ADCs with a shared antibody framework: trastuzumab linked to the microtubule inhibitor monomethyl auristatin E (T-MMAE) and the topoisomerase inhibitor deruxtecan (T-DXd). Treatment with T-MMAE led to a significant increase in immune cell infiltration, whereas T-DXd–treated tumors had fewer immune cells albeit comparable tumor cytotoxicity. When combined with anti–PD-1 immunotherapy, similar additive effects on the primary antitumor response were observed for both ADCs. A key qualitative difference between the two ADCs was observed in the phenotypes of myeloid APCs; T-MMAE treatment resulted in greater immune cell infiltration within the tumor, including macrophages that showed increased gene expression of F4/80, CD206, and IL10RA. In contrast, tumors treated with T-DXd exhibited a lower proportion of macrophages, but APCs in these tumors displayed heightened levels of the CD80 costimulatory molecule. The secondary antitumor response mediated by memory CD8+ T cells was crucial for the formation of immunologic memory induced by both ADCs. Therefore, our findings reveal that, after ADC-mediated tumor cytotoxicity, different ADC payloads elicit distinct immunologic responses characterized by varying levels of myeloid cell activation within the TME.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
EMT6.hHER2 tumor growth in vivo.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
EMT6.hHER2 tumor growth in vivo.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Anti-tumor efficacy induced by anti-PD-1 in EMT6.hHER2 syngeneic mouse model.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Anti-tumor efficacy induced by anti-PD-1 in EMT6.hHER2 syngeneic mouse model.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
List of antibodies for FACS immunophenotyping
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
List of antibodies for FACS immunophenotyping
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
FACS immunophenotyping of EMT6.hHER2 tumors.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
FACS immunophenotyping of EMT6.hHER2 tumors.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Depletion efficiency of CD4 and CD8 T cells.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Depletion efficiency of CD4 and CD8 T cells.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
QPCR Assay ID for select genes
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
QPCR Assay ID for select genes
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Immune memory in complete responders (CRs) generated upon ADC and anti-PD-1 combination therapy.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
Immune memory in complete responders (CRs) generated upon ADC and anti-PD-1 combination therapy.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
No cytotoxic activity of hHER2-targed ADCs with the parental EMT6 cell line that does not express hHER2.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
No cytotoxic activity of hHER2-targed ADCs with the parental EMT6 cell line that does not express hHER2.